12-Week Open-Label Extension Study of TNX-102 SL in PTSD Patients

NCT03110575 · clinicaltrials.gov ↗
PHASE3
Phase
TERMINATED
Status
190
Enrollment
INDUSTRY
Sponsor class

Stopped Stopped early due to inadequate separation on primary efficacy endpoint in the lead-in HONOR study, TNX-CY-P301

Conditions

Interventions

Sponsor

Tonix Pharmaceuticals, Inc.

Collaborators